SEARCH

SEARCH BY CITATION

References

  • 1
    McLaren C, Chen MS, Barbhaiya RH, Buroker RA, Oleson FB. Preclinical investigations of FIAU, an anti-herpes agent. In: KonoR, ed. Herpes Viruses and Viral Chemotherapy. New York: Elsevier Science Publishers, 1985;5761.
  • 2
    Schinazi RF, Fox JJ, Watanabe KA, Nahmias AJ. Activities of 1-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-5-iodocytosine and its metabolites against herpes simplex virus types 1 and 2 in cell culture and in mice infected intracerebrally with herpes simplex virus type 2. Antimicrob Agents Chemother 1986; 29:7784.MEDLINE
  • 3
    Korba BE, Gerin JL. Use of a standardized cell culture assay to assess activities of nucleoside analogs against hepatitis B virus replication. Antiviral Res 1992; 19:5570.MEDLINE
  • 4
    Staschke KA, Colacino JM, Mabry TE, Jones CD. The in vitro anti-hepatitis B virus activity of FIAU [1-(2′-deoxy-2′-fluoro-1-β-D-arabinofuranosyl-5-iodo)uracil] is selective, reversible, and determined, at least in part, by the host cell. Antiviral Res 1994; 23:4561.MEDLINE
  • 5
    McKenzie R, Fried MW, Sallie R, Conjeevaram H, Di Bisceglie AM, Park Y, Savarese B, et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 1995; 333:10991105.MEDLINE
  • 6
    Stevenson W, Gaffey M, Ishitani M, McCullough C, Dickson R, Caldwell S, Lobo P, et al. Clinical course of four patients receiving the experimental antiviral agent fialuridine for the treatment of chronic hepatitis B infection. Transplant Proc 1995; 27:12191221.MEDLINE
  • 7
    Witt A, Williams R, Pierce R. Report of an FDA Task Force. Fialuridine: Hepatic and Pancreatic Toxicity. Washington, DC: Food and Drug Administration, November 12, 1993:191.
  • 8
    ManningFJ, SwartzM, eds. Review of the Fialuridine (FIAU) Clinical Trials. Institute of Medicine. Washington, DC: National Academy Press. 1995;1269.
  • 9
    Richardson RC, Engelhardt JA, Bowsher RR. Fialuridine accumulates in DNA of dogs, monkeys, and rats following long-term oral administration. Proc Natl Acad Sci U S A 1994; 91:1200312007.MEDLINE
  • 10
    Parker WB, Cheng YC. Mitochondrial toxicity of antiviral nucleoside analogs. J NIH Res 1994; 6:5761.
  • 11
    Tennant BC, Gerin JL. The woodchuck model of hepatitis B virus infection. In: AriasIM, BoyerJ, FaustoN, JakobyWB, SchachterD, ShafritzDA, eds. The Liver: Biology and Pathobiology. 3rd ed. New York: Raven, 1994;14551466.
  • 12
    Summers J, Smolec JM, Snyder R. A virus similar to human hepatitis B virus associated with hepatitis and hepatoma in woodchucks. Proc Natl Acad Sci U S A 1978; 75:45334537.MEDLINE
  • 13
    Roth L, King JM, Hornbuckle WE, Harvey HJ, Tennant BC. Chronic hepatitis and hepatocellular carcinoma associated with persistent woodchuck hepatitis virus infection. Vet Pathol 1985; 22:338343.MEDLINE
  • 14
    Popper H, Roth L, Purcell RH, Tennant BC, Gerin JL. Hepatocarcinogenicity of the woodchuck hepatitis virus. Proc Natl Acad Sci U S A 1987; 84:866870.MEDLINE
  • 15
    Korba BE, Wells FV, Baldwin B, Cote PJ, Tennant BC, Popper H, Gerin JL. Hepatocellular carcinoma in woodchuck hepatitis virus-infected woodchucks. Presence of viral DNA in tumor tissue from chronic carriers and animals serologically recovered from acute infections. Hepatology 1989; 9:461470.MEDLINE
  • 16
    Cote PJ, Roneker C, Cass K, Schödel F, Peterson D, Tennant B, de Noronha F, et al. New enzyme immunoassays for the serologic detection of woodchuck hepatitis virus infection. Viral Immunol 1993; 6:161169.MEDLINE
  • 17
    Bowsher RR, Compton JA, Kirkwood JA, Place GD, Jones CD, Mabry TE, Hyslop DL, et al. Sensitive and specific radioimmunoassay for fialuridine: initial assessment of pharmacokinetics after single oral doses to healthy volunteers. Antimicrob Agents Chemother 1994; 38:21342142.MEDLINE
  • 18
    Tennant BC, Baldwin BH, Hornbuckle WE, Korba BE, Cote PJ, Gerin JL. Animal models in the preclinical assessment of therapy for viral hepatitis. Antiviral Ther 1996; 1(suppl 4):4752.
  • 19
    Lewis W, Griniuviene B, Tankersley KO, Levine ES, Montione R, Engelman L, de Courten-Myers G, et al. Depletion of mitochondrial DNA, destruction of mitochondria, and accumulation of lipid droplets result from fialuridine treatment in woodchucks (Marmota monax). Lab Invest 1997; 76:7787.MEDLINE
  • 20
    Corkey BE, Hale DE, Glennon MC, Kelly RI, Coates PM, Kilpatrick L, Stanley CA. Relationship between unusual hepatic acyl coenzyme A profiles and the pathogenesis of Reye's syndrome. J Clin Invest 1988; 82:782788.MEDLINE
  • 21
    Heubi JE, Partin JC, Partin JS, Schubert WK. Reye's syndrome: current concepts. Hepatology 1987; 7:155164.MEDLINE
  • 22
    Chattha G, Arieff AI, Cummings C, Tierney LM. Lactic acidosis complicating the acquired immunodeficiency syndrome. Ann Intern Med 1993; 118:3739.MEDLINE
  • 23
    Lai KK, Gang DL, Zawacki JK, Cooley TP. Fulminant hepatic failure associated with 2′,3′-dideoxyinosine (ddI). Ann Intern Med 1991; 115:283284.MEDLINE
  • 24
    Bissuel F, Bruneel F, Habersetzer F, Chassard D, Cotte L, Chevallier M, Bernuau J, et al. Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy. J Int Med 1994; 235:367371.
  • 25
    Freiman JP, Helfert KE, Hamrell MR, Stein DS. Hepatomegaly with severe steatosis in HIV-seropositive patients. AIDS 1993; 7:379385.MEDLINE
  • 26
    Jolliet P, Widmann JJ. Reye's syndrome in adults with AIDS. Lancet 1990; 335:1457.MEDLINE
  • 27
    Gopinath R, Hutcheon M, Cheema-Dhadli S, Halperin M. Chronic lactic acidosis in a patient with acquired immunodeficiency syndrome and mitochondrial myopathy: biochemical studies. J Am Soc Nephrol 1992; 3:12121219.MEDLINE
  • 28
    Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nat Med 1995; 1:417422.MEDLINE
  • 29
    Chen C-H, Cheng Y-C. Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2′,3′-dideoxycytidine. J Biol Chem 1989; 264:1193411937.MEDLINE
  • 30
    Chen C-H, Vasquez-Padua M, Cheng Y-C. Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity. Mol Pharmacol 1991; 39:625628.MEDLINE
  • 31
    Chen C-H, Cheng Y-C. The role of cytoplasmic deoxycytidine kinase in the mitochondrial effects of the anti-human immunodeficiency virus compound, 2′,3′-dideoxycytidine. J Biol Chem 1992; 267:28562859.MEDLINE
  • 32
    Medina DJ, Tsai C-H, Hsiung GD, Cheng Y-C. Comparison of mitochondrial morphology, mitochondrial DNA content, and cell viability in cultured cells treated with three anti-human immunodeficiency virus dideoxynucleosides. Antimicrob Agents Chemother 1994; 38:18241828.MEDLINE
  • 33
    Bridges EG, Kukhanova M, Pai SB, Gullen E, Zhu YL, Cheng YC. Potential action of 1(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-5-iodouracil on mitochondrial DNA in human cells [Abstract]. Am Assoc Cancer Res 1994; 35:311.
  • 34
    Colacino JM, Malcolm SK, Jaskunas SR. Effect of fialuridine on replication of mitochondrial DNA in CEM cells and in human hepatoblastoma cells in culture. Antimicrob Agents Chemother 1994; 38:19972002.MEDLINE
  • 35
    Martin JL, Brown CE, Matthews-Davis N, Reardon JE. Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. Antimicrob Agents Chemother 1994; 38:27432749.MEDLINE
  • 36
    Klecker RW, Katki AG, Collins JM. Toxicity, metabolism, DNA incorporation with lack of repair, and lactate production for 1-(2′-fluoro-2′-deoxy-β-D-arabinofuranosyl)-5-iodouracil in U-937 and MOLT-4 cells. Mol Pharmacol 1994; 46:12041209.MEDLINE
  • 37
    Cui L, Yoon S, Schinazi RF, Sommadossi J-P. Cellular and molecular events leading to mitochondrial toxicity of 1-(2-deoxy-2-fluoro-1-β-D-arabinofuranosyl)-5-iodouracil in human liver cells. J Clin Invest 1995; 95:555563.MEDLINE
  • 38
    Lewis W, Levine ES, Griniuviene B, Tankersley KO, Colacino JM, Sommadossi J-P, Watanabe KA, et al. Fialuridine and its metabolites inhibit DNA polymerase γ at sites of multiple adjacent analog incorporation, decrease mtDNA abundance, and cause mitochondrial structural defects in cultured hepatoblasts. Proc Natl Acad Sci U S A 1996; 93:35923597.MEDLINE
  • 39
    Colacino JM, Horn JW, Horn DM, Richardson FC. Incorporation of fialuridine (FIAU) into mitochondrial DNA and effects of FIAU on the morphology of mitochondria in human hepatoblastoma cells. Toxicol In Vitro 1996; 10:297303.
  • 40
    Lewis W, Meyer RR, Simpson JF, Colacino JM, Perrino FW. Mammalian DNA polymerases alpha, beta, gamma, delta, and epsilon incorporate fialuridine (FIAU) monophosphate into DNA and are inhibited competitively by FIAU triphosphate. Biochemistry 1994; 33:1462014624.MEDLINE
  • 41
    Cherrington JM, Allen SJ, McKee BH, Chen MS. Kinetic analysis of the interaction between the diphosphate of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, ddCTP, AZTTP, and FIAUTP with human DNA polymerases β and γ. Biochem Pharmacol 1994; 48:19861988.MEDLINE
  • 42
    Sallie R, Kleiner D, Richardson F, Conjeevaram H, Zullo S, Mutimer D, Hoover S, et al. Mechanisms of FIAU induced hepatotoxicity [Abstract]. Hepatology 1994; 20:209A.
  • 43
    Helvering LM, Richardson KA, Englehardt JA, Richardson FC. Fialuridine (FIAU) depletes mitochondrial DNA in the liver and heart of rat, dog and monkey during long-term oral administration [Abstract]. Am Assoc Cancer Res 1995; 36:358.
  • 44
    Chou T-C, Feinberg A, Grant AJ, Vidal P, Reichman U, Watanabe KA, Fox JJ, et al. Pharmacological disposition and metabolic fate of 2′-fluoro-5-iodo-1-β-D-arabinofuranosylcytosine in mice and rats. Cancer Res 1981; 41:33363342.MEDLINE
  • 45
    Grant AJ, Feinberg A, Chou TC, Watanabe KA, Fox JJ, Philips FS. Incorporation of metabolites of 2′-fluoro-5-iodo-1-β-D-arabinofuranosylcytosine into deoxyribonucleic acid of neoplastic and normal mammalian tissues. Biochem Pharmacol 1982; 31:11031108.MEDLINE
  • 46
    Chen MS, Van Nostrand M, Oshana SC. Quantitative determination of antiviral nucleoside analog in DNA. Anal Biochem 1986; 156:300304.MEDLINE
  • 47
    Richardson FC, Horn DM, Scheuring JC, Huffman DM, Oakes DW, Englehardt JA, Kirkwood JA, et al. Kinetics of accumulation of fialuridine (FIAU) in F-344 rat during long-term oral administration [Abstract]. Am Assoc Cancer Res 1995; 36:358.
  • 48
    Gschwentner M, Susanna A, Woll E, Ritter M, Nagl UO, Schmarda A, Laich A, et al. Antiviral drugs from the nucleoside analog family block volume-activated chloride channels. Mol Med 1995; 1:407417.MEDLINE
  • 49
    Aguilar HI, Botla R, Arora AS, Bronk S, Gores GJ. Induction of the mitochondrial permeability transition by protease activity in rats: a mechanism of hepatocyte necrosis. Gastroenterology 1996; 110:558566.MEDLINE
  • 50
    Carini R, Autelli R, Bellomo G, Dianzani MU, Albano E. Sodium-mediated cell swelling is associated with irreversible damage in isolated hepatocytes exposed to hypoxia or mitochondrial toxins. Biochem Biophys Res Commun 1995; 206:180185.MEDLINE
  • 51
    Fourel I, Hantz O, Watanabe KA, Jacquet C, Chomel B, Fox JJ, Trepo C. Inhibitory effects of 2′-fluorinated arabinosyl-pyrimidine nucleosides on woodchuck hepatitis virus replication in chronically infected woodchucks. Antimicrob Agents Chemother 1990; 34:473475.MEDLINE
  • 52
    Korba BE, Cote PJ, Tennant BC, Gerin JL. Woodchuck hepatitis virus infection as a model for the development of antiviral therapies against HBV. In: HollingerFB, LemonSM, MargolisH, eds. Viral Hepatitis and Liver Disease. Baltimore: Williams & Wilkins. 1991;663665.